Scrip senior writer Joseph Haas discusses the potential impact of the recent FDA staff cuts with attorneys Andrew Goodman of Paul Hastings LLP and Alan Minsk of Arnall Golden Gregory, as well as Naya Therapeutics CEO Daniel Teper

Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Share Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

Sign up to save your podcasts

Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

More shows like Citeline Podcasts

The Documentary Podcast

Nature Podcast

Economist Podcasts

Marketplace

Marketplace All-in-One

Exchanges

Decoder with Nilay Patel

The Long Run with Luke Timmerman

The Readout Loud

FT News Briefing

The Intelligence from The Economist

The Rachman Review

BioCentury This Week

Biotech Hangout

Money Stuff: The Podcast